Incannex Healthcare Limited (IHL.AX)
| Previous close | 0.0690 |
| Open | 0.0680 |
| Bid | 0.0700 x 19574500 |
| Ask | 0.0690 x 30420000 |
| Day's range | 0.0660 - 0.0690 |
| 52-week range | 0.0640 - 0.3200 |
| Volume | |
| Avg. volume | 4,549,249 |
| Market cap | 104.743M |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 30 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireIncannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023
MELBOURNE, Australia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing cannabinoid pharmaceutical medicines and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023. Incannex will be presenting and taking one on one meetings virtually. Mr
Simply Wall St.Companies Like Incannex Healthcare (ASX:IHL) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
MELBOURNE, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that its subsidiary Psychennex Pty Ltd has commenced preparations of an investigational new drug (‘IND’) application to the U.S. Food and Drug Administration (‘FDA’) for th
